Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Short Interest Update

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPHGet Free Report) saw a significant increase in short interest in the month of January. As of January 15th, there was short interest totalling 2,940,000 shares, an increase of 5.8% from the December 31st total of 2,780,000 shares. Currently, 8.2% of the shares of the company are short sold. Based on an average trading volume of 455,100 shares, the short-interest ratio is currently 6.5 days.

Amphastar Pharmaceuticals Stock Down 0.8 %

Shares of NASDAQ:AMPH opened at $54.94 on Wednesday. The company has a market capitalization of $2.63 billion, a PE ratio of 21.46, a price-to-earnings-growth ratio of 0.68 and a beta of 0.93. Amphastar Pharmaceuticals has a 52-week low of $29.91 and a 52-week high of $67.66. The company has a fifty day moving average of $57.86 and a 200-day moving average of $53.97. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.68 and a current ratio of 2.11.

Amphastar Pharmaceuticals (NASDAQ:AMPHGet Free Report) last posted its quarterly earnings data on Wednesday, November 8th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.41. The business had revenue of $180.56 million during the quarter, compared to the consensus estimate of $170.65 million. Amphastar Pharmaceuticals had a return on equity of 26.68% and a net margin of 22.50%. On average, equities analysts predict that Amphastar Pharmaceuticals will post 2.91 EPS for the current fiscal year.

Insider Transactions at Amphastar Pharmaceuticals

In other news, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $57.90, for a total transaction of $28,950.00. Following the completion of the sale, the director now owns 81,333 shares in the company, valued at $4,709,180.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Rong Zhou sold 4,316 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $58.58, for a total value of $252,831.28. Following the completion of the sale, the executive vice president now directly owns 112,420 shares in the company, valued at $6,585,563.60. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Floyd F. Petersen sold 500 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $57.90, for a total value of $28,950.00. Following the completion of the sale, the director now owns 81,333 shares of the company’s stock, valued at $4,709,180.70. The disclosure for this sale can be found here. Insiders sold a total of 282,860 shares of company stock worth $16,055,773 over the last quarter. Company insiders own 27.80% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of AMPH. McGlone Suttner Wealth Management Inc. acquired a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $28,000. West Tower Group LLC bought a new stake in Amphastar Pharmaceuticals during the second quarter valued at $39,000. Point72 Middle East FZE bought a new stake in Amphastar Pharmaceuticals during the fourth quarter valued at $50,000. Ronald Blue Trust Inc. boosted its position in Amphastar Pharmaceuticals by 821.5% during the third quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock valued at $55,000 after acquiring an additional 1,068 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Amphastar Pharmaceuticals by 99.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after acquiring an additional 628 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on AMPH. Bank of America began coverage on Amphastar Pharmaceuticals in a research note on Friday, November 17th. They issued a “neutral” rating and a $63.00 price target for the company. StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, January 23rd.

Get Our Latest Stock Report on AMPH

About Amphastar Pharmaceuticals

(Get Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).

Recommended Stories

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.